May 2022 Report This May 2022 549-page NIH report represents a significant breakthrough in autoimmune research focus. Its recommendations have major downstream implications for CDC statistics, basic research, R&D, medical education & clinical guidelines. Funded and launched in 2019, before the pandemic but even more relevant since COVID-19 spotlighted post-viral
Data Issues in Autoimmune Data for autoimmune diseases are substantially lacking and inconsistent. The US gathers no statistics on autoimmune diseases as a group, nor even national data on marquee diseases. Therefore, total autoimmune incidence & prevalence figures are, at best, estimates. Unlike cancer, there is no national strategic research
The Problem: We Don’t Really Know! The problem with estimating the total cost burden of the autoimmune disease (AIID) epidemic is that we really don’t know! A May 2022 NIH report validates our long-held belief that missing and inconsistent data for autoimmune diseases (AIIDs) are at the root of the
NIH Report Shows Why The AIID Epidemic is Invisible An NIH research report on autoimmune disease, published May, 2022, explains why, despite affecting more Americans than cancer, autoimmune and immunoinflammatory diseases (AIIDs) remain an invisible epidemic. Autoimmunity is an orphaned research field of patchwork studies of some 80-150 individual diseases.
Since 2010, we have sought autoimmune disease (AIID) incidence and prevalence data. Despite efforts by independent organizations like AARDA/AA, AIR and many single disease groups, we never found total national autoimmune statistics. NIH/CDC statistics bury AIIDs within siloed categories: Arthritis, diabetes, or by medical specialty: rheumatology, neurology, dermatology, endocrine, etc.